Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study

• ClinicalTrials.gov Identifier: NCT00273364
• Recruitment Status: Completed
• First Posted: January 9, 2006
• Results First Posted: August 12, 2020
• Last Update Posted: August 12, 2020
• Sponsor: Northwestern University
• Collaborators: Uppsala University; Sheffield Teaching Hospitals NHS Foundation Trust; University of Sao Paulo
• Information provided by (Responsible Party): Richard Burt, MD, Northwestern University

Tracking Information

• First Submitted Date: January 5, 2006
• First Posted Date: January 9, 2006
• Results First Submitted Date: July 15, 2020
• Results First Posted Date: August 12, 2020
• Last Update Posted Date: August 12, 2020
• Actual Study Start Date: November 16, 2005
• Actual Primary Completion Date: January 5, 2017 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 10, 2020)

Expanded Disability Status Scale (EDSS) Improvement [ Time Frame: Pre Treatment, 6 and 12 months Post Treatment ]

The EDSS scale ranges from 0 to 10 in 0.5 increments that represent higher levels of disability. Improvement in EDSS is defined by both a 0.5 or 1.0 points sustained for more than 6 months.

• Original Primary Outcome Measures (submitted: January 5, 2006): EDSS
• Current Secondary Outcome Measures: Not Provided
• Original Secondary Outcome Measures: Not Provided
• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
• Official Title: Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
• Brief Summary: Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares. Over years or decades, virtually all cases transition into a progressive disease in which insidious and slow neurologic deterioration occurs with or without acute flares. Relapsing-remitting disease is often responsive to immune suppressive or modulating therapies, while immune based therapies are generally ineffective in patients with a progressive clinical course. This clinical course and response to immune suppression, as well as neuropathology and neuroimaging studies, suggest that disease progression is associated with axonal atrophy. Disability correlates better with measures of axonal atrophy than immune mediated demyelination. Therefore, immune based therapies, in order to be effective, need to be started early in the disease course while MS is predominately an immune-mediated and inflammatory disease. While current immune based therapies delay disability, no intervention has been proven to prevent progressive disability. We propose, as a randomized study, autologous unmanipulated PBSCT using a conditioning regimen of cyclophosphamide and rabbit antithymocyte globulin (rATG) versus FDA approved standard of care (i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) in patients with inflammatory (relapsing) MS despite treatment with alternate approved therapy.

Detailed Description

To assess the efficacy of autologous PBSCT versus FDA approved standard of care ( i.e. interferon, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, or tecfidera) for inflammatory multiple sclerosis (MS) failing failing alternate approved therapy. The endpoints to be considered in this study are:

2.1 Primary Endpoint:

Disease progression, defined as a 1 point increase in the Expanded Disability Status Scale (EDSS) on consecutive evaluations at least 6 months apart and not due to a non-MS disease process. Patients will be followed for 5 years after randomization.

• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Multiple Sclerosis

Intervention

• Procedure: Hematopoietic Stem Cell Therapy
  After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
  Other Name: stem cell infusion
• Drug: Standard treatment with a conventional drug
  Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or Gilenya (fingolimod)
  Other Name: standard of care

Study Arms

• Experimental: Hematopoietic Stem Cell Transplantation
  Hematopoietic Stem Cell Therapy will be performed as follows: Autologous stem cells will be infused after conditioning with Cyclophosphamide and rATG
  Intervention: Procedure: Hematopoietic Stem Cell Therapy
• Active Comparator: Standard therapy for MS
  Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), Gilenya (fingolimod) or Dimethyl fumarate (Tecfidera or BG-12)
  Intervention: Drug: Standard treatment with a conventional drug

Publications *

• Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, Fagius J, Rose J, Nelson F, Barreira AA, Carlson K, Han X, Moraes D, Morgan A, Quigley K, Yaung K, Buckley R, Alldredge C, Clendenan A, Calvario MA, Henry J, Jovanovic B, Helenowski IB. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019 Jan 15;321(2):165-174. doi: 10.1001/jama.2018.18743.
• Burman J, Fransson M, Totterman TH, Fagius J, Mangsbo SM, Loskog AS. T-cell responses after haematopoietic stem cell transplantation for aggressive relapsing-remitting multiple sclerosis. Immunology. 2013 Oct;140(2):211-9. doi: 10.1111/imm.12129.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 5, 2006): 110
• Original Enrollment: Same as current
• Actual Study Completion Date: August 30, 2019
• Actual Primary Completion Date: January 5, 2017 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

1. Age between18-55, inclusive.
2. Diagnosis of MS using revised McDonald criteria of clinically definite MS (Appendix I).
3. An EDSS score of 2.0 to 6.0 (Appendix II).

4. Inflammatory disease despite treatment with standard disease modifying therapy including at least 6 months of interferon or copaxone. Inflammatory disease is defined based on both MRI (gadolinium enhancing lesions) and clinical activity (acute relapses *treated with IV or oral high dose corticosteroids and prescribed by a neurologist). Minimum disease activity required for failure is defined as: a) two or more *steroid treated clinical relapses with documented new objective signs on neurological examination documented by a neurologist within the year prior to the study, or b) one *steroid treated clinical relapse within the year prior to study and evidence on MRI of active inflammation (i.e., gadolinium enhancement) within the last 12 months on an occasion separate from the clinical relapse (3 months before or after the clinical relapse).

   • A steroid treated relapse will include a relapse that was severe enough to justify treatment but due to patient intolerance of steroids, or a history of non-response to steroids, they were offered but not used.

Exclusion Criteria**

1. Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy.
2. Prior history of malignancy except localized basal cell, squamous skin cancer or carcinoma in situ of the cervix. Other malignancies for which the patient is judged to be cured, such as head and neck cancer, or breast cancer will be considered on an individual basis.
3. Positive pregnancy test
4. Inability or unwillingness to pursue effective means of birth control from the time of evaluation for eligibility until 6 months posttransplant (if on transplant) or until appropriate for non-transplant treatment (if on control arm). Effective birth control is defined as 1) abstinence defined as refraining from all acts of vaginal intercourse; 2) consistent use of birth control pills; 3) injectable birth control methods (Depo-provera, Norplant); 4) tubal sterilization or male partner who has undergone vasectomy; 5) placement of an intrauterine device (IUD); or 6) use, with every act of intercourse, of diaphragm with contraceptive jelly and/or condoms with contraceptive foam.
5. Failure to willingly accept or comprehend irreversible sterility as a side effect of therapy
6. Forced expiratory volume at one second (FEV1) / forced vital capacity (FVC) < 60% of predicted after bronchodilator therapy (if necessary)
7. Diffusing capacity of lung for carbon monoxide (DLCO) < 50% of predicted (for the transplant arm)
8. Resting left ventricular ejection fraction (LVEF) < 50 %
9. Bilirubin > 2.0 mg/dl
10. Serum creatinine > 2.0 mg/dl
11. Known hypersensitivity to mouse, rabbit, or E. Coli derived proteins, or to iron compounds/medications
12. Presence of metallic objects implanted in the body that would preclude the ability of the patient to safely have MRI exams
13. Diagnosis of primary progressive MS
14. Diagnosis of secondary progressive MS
15. Platelet count < 100,000/ul, white blood cell count (WBC) < 1,500 cells/mm3
16. Psychiatric illness, mental deficiency or cognitive dysfunction making compliance with treatment or informed consent impossible
17. Active infection except asymptomatic bacteriuria
18. Use of natalizumab (Tysabri) within the previous 6 months
19. Use of fingolimod (Gilenya) within the previous 3 months
20. Use of teriflunomide (Aubagio) within the previous 2 years unless cleared from the body (plasma concentration < 0.02mcg/ml) following elimination from the body with cholestyramine 8g three times a day for 11 days
21. Prior treatment with CAMPATH (alemtuzumab)
22. Prior treatment with mitoxantrone
23. Any hereditary neurological disease such as Charcot-Marie-Tooth disease (CMT) or Spinocerebellar ataxia (SCA) are contraindications

24. Use of tecfidera within the previous 3 months

    • For patients who clearly have inflammatory disease, an exception can be made if agreed upon by study PI and at least two study neurologists.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years to 55 Years (Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT00273364
• Other Study ID Numbers: DI MS.Randomized2004
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Richard Burt, MD, Northwestern University
• Original Responsible Party: Not Provided
• Current Study Sponsor: Northwestern University
• Original Study Sponsor: Same as current

Collaborators

• Uppsala University
• Sheffield Teaching Hospitals NHS Foundation Trust
• University of Sao Paulo

Investigators

• Principal Investigator: Richard Burt, MD; Northwestern University

• PRS Account: Northwestern University
• Verification Date: April 2019